Dawn Fishbein, MD, is an attending physician, Infectious Diseases, at MedStar Washington Hospital Center. Before joining the Hospital Center, she was an attending physician in Infectious Diseases at Mount Sinai Medical Center in New York, where she created an on-site integrated clinic for people infected with both HIV and hepatitis C. Her research to assess factors associated with engaging and accessing care for people infected with hepatitis C was funded by the National Institutes of Health.
At the Hospital Center, she is collaborating with the Gastroenterology Department to strengthen a program to provide care for patients with hepatitis B and C infections. Prior to her current position, she was the medical director of the District of Columbia's Partnership for HIV/AIDS Progress Subspecialty Clinics.
Dr. Fishbein serves as a reviewer for the Journal of Acquired Immune Deficiency Syndrome and ClinicalInfectious Diseases. Her research has been published in peer-reviewed journals, including AIDS Research and Treatment, Journal of Medical Virology and Journal of Clinical Outcomes Medicine. She is a member of the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America (IDSA), and she served as an elected councilor for the IDSA's New York chapter. She is certified in Internal Medicine and Infectious Diseases.
Dr. Fishbein received her medical degree from the Albert Einstein School of Medicine, Bronx, NY. She continued her training with a residency at Mount Sinai Medical Center and a fellowship in Infectious Disease at the Montefiore Medical Center/Albert Einstein College of Medicine in New York. During her fellowship, Dr. Fishbein also completed a Master of Science degree in clinical research. Her Master of Business Administration degree is from Columbia University.
Dr. Fishbein's research interests include
- Infectious diseases
- Viral hepatitis
- HIV and hepatitis co-infection
- Testing, evaluation and education regarding liver disease
- Hepatitis A, B and C
New Treatment Methodologies for Patients with Hepatitis C
As an associate investigator, Dr. Fishbein has led trials of new drug therapies for patients with hepatitis C. These trials have been funded by public (National Institutes of Health) and private (Gilead, Merck and Romark) sponsors.
Effects of Angiotensin Converting Enzyme Inhibitors on Liver Fibrosis in HIV and Hepatitis C Coinfection
Liver fibrosis is accelerated in HIV and hepatitis C co-infection. In this research, published in AIDS Research and Treatment (2012;978790), Dr. Fishbein and colleagues investigated whether angiotensin converting enzyme inhibitors attenuate liver fibrosis in HIV and Hepatitis C coinfection.
- Research Areas
- Other Medical